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Introduction and Objective. Iatrogenic male stress urinary incontinence (SUI) aﬀects a percentage of men undergoing urologic
procedures with a signiﬁcant impact on quality of life. The treatment of male SUI has evolved signiﬁcantly with multiple current
options for treatment available. The current paper discusses preoperative evaluation of male SUI, available surgical options with
reportedoutcomes,andpostoperativecomplicationmanagement.Methods.ApubMedreviewofavailableliteraturewasperformed
and summarized on articles reporting outcomes of placement of the artiﬁcial urinary sphincter (AUS) or male slings including
the bone anchored sling (BAS), retrourethral transobturator sling (RTS), adjustable retropubic sling (ARS), and quadratic sling.
Results. Reported rates of success (variably deﬁned) for BAS, RTS, ARS, and AUS are 36–67%, 9–79%, 13–100%, and 59–91%
respectively. Complications reported include infection, erosion, retention, explantation, and transient pain. Male slings are more
commonly performed in cases of low-to-moderate SUI with decreasing success with higher degrees of preoperative incontinence.
Conclusions. An increasing number of options continue to be developed for the management of male SUI. While the AUS remains
the gold-standard therapy for SUI, male sling placement is a proven viable alternative therapy for low-to-moderate SUI.
1.Introduction
Urinary incontinence is estimated to aﬀect 12–17% of US
males, with increasing prevalence associated with aging
[1, 2]. Stress urinary incontinence (SUI) as a subtype has
been deﬁned by the International Continence Society as the
complaint of involuntary leakage on eﬀort or exertion, or
on sneezing or coughing [3]. Although any surgical or radio-
therapeutic manipulation of the external urinary sphincter
may result in SUI, radical prostatectomy (RP), transurethral
resection of the prostate (TURP), and radiation therapy
are most commonly associated with RP accounting for the
majority of iatrogenic etiologies. The true prevalence of SUI
following RP is unknown with widely varying estimates
reported from 2 to 43%, which is likely reﬂective of diﬀering
surgical techniques, methodology, deﬁnitions, and followup
performed, among others [4–9]. External beam radiation
therapy and TURP are less commonly associated with SUI,
with reported outcomes ranging from 1 to 16% and 1 to 3%,
respectively [10–12]. Given that prostate cancer is the most
commonlydiagnosedmalignancyinUSmales,thetruescope
and impact of iatrogenic male SUI on quality of life (QOL) is
likely signiﬁcant.
The treatment of male SUI has continued to improve
since the introduction of the ﬁrst externally worn urethral
cuﬀ by Foley in 1949. Subsequent modiﬁcations of an inter-
nally placed prosthesis by Kaufman in 1973 (Kaufmann III)
and an internal reservoir by Rosen in 1976 led to the ﬁrst
completely internalized artiﬁcial urinary sphincter (AUS).
Despite initial enthusiasm with the procedure, signiﬁcant
complications arose including urethral erosions and ﬁstulae
secondary to the continuously elevated urethral occlusion
pressures. Subsequent advancements by American Medical
Systems (AMS, Minnetonka, Minnesota) with the AS 721 led
to reported success rates of 79% among 34 patients treat-
ed by Scott and colleagues [13]. Further improvements were
later introduced including automatic cuﬀ closure, cuﬀ deac-
tivation, and modiﬁcations to the narrow-backed cuﬀ,a l lo f
which have continued to improve outcomes while decreasing
complication rates. Currently, the most commonly utilized2 Advances in Urology
AUS is the AMS 800 (AMS, Minnetonka, Minnesota) which
consists of a pump, reservoir, and urinary cuﬀ. Since its
popularization, the AUS has remained the gold-standard
treatment for male SUI.
Beginning in the late 1990s, the male sling was intro-
duced as a surgical alternative to the AUS for patients with
low volume incontinence (1–3 pads). Among other factors,
one notable diﬀerence with male slings compared to the AUS
is the lack of mechanical components, which reduces the
potential for device failure. Although several variations on
sling design exist, the most commonly published series
available report on three speciﬁc designs, the suburethral
bone-anchored slings (BAS), retrourethral transobturator
slings (RTS), and adjustable retropubic slings (ARS).
With an increasing number of options available for the
treatment of male SUI, it is important for treating clini-
cians to be aware of available therapeutic options, compar-
ative outcomes, and associated complications. The current
paper is outlined to review the clinical evaluation of males
presenting with SUI, discuss the male sling and AUS as
treatment options, review reported outcomes on therapies,
brieﬂy discuss management of common postoperative com-
plications, and highlight potential future perspectives.
2. ClinicalEvaluation
Males presenting with stress urinary incontinence should
undergo a complete history and physical examination to in-
clude reviewing the underlying etiology and duration of the
incontinence, current and prior urinary symptoms, history
of genitourinary pathology (ex, nephrolithiasis, urothelial
carcinoma), urinary tract infections, the degree and subjec-
tive bother of incontinence, and a review of prior proce-
dures including radiation. Additional quantitative measures
which may be employed include obtaining pad weights and
standardized QOL questionnaires [14–16]. Patients should
furtherundergoagenitourinaryexaminationandbeassessed
as to their physical and mental capacity to function a poten-
tial AUS device.
Further testing may be individualized based on results
obtained during the history and physical examination. All
patients should undergo a routine urinalysis and postvoid
residual to rule out concurrent infection and any degree of
urinaryretention.Additionaltestingmaybeobtainedasclin-
icallyindicatedincludingimaging(ex,historyofnephrolithi-
asis, urothelial carcinoma), urine cytology (ex, irritative
voiding symptoms, history of urothelial carcinoma), and
PSA. Urodynamic studies are not routinely performed and
are predominantly reserved for cases of suspected elevated
bladder pressures or indeterminate/multifactorial etiologies
for incontinence [17]. It is the author’s practice to perform
a cystoscopy on all patients considering surgical treatments
for SUI to rule out anatomic abnormalities (ex, stricture,
bladder neck contracture). Additionally, this permits ﬁlling
of the bladder with saline followed by direct observation of
the degree of stress urinary incontinence experienced.
Surgical candidates desiring a male sling or artiﬁcial
urinary sphincter should be 6–12 months out from the
initial event resulting in SUI as this permits resolution
of concomitant urinary symptoms and allows suﬃcient
time for spontaneous recovery of continence. Additionally,
patients should ideally have a normal bladder capacity and
compliance, have isolated SUI without signiﬁcant urgency,
be free of intraurethral and/or intravesical pathology, have
suﬃcient physical and mental capacity to function a
potential device, and be able to maintain his activities of
daily living without need for assistance. Although none
of these factors would preclude surgical intervention, each
should be weighed in the clinical decision so as to reduce
potential future complications. Patients with prior histories
of urothelial carcinoma, nephrolithiasis, urethral stricture
disease, and bladder neck contractures, among others should
demonstrate a suﬃcient period of disease stability prior to
consideration of sling/AUS placement to reduce the risk of
erosions resulting from repeated interventions.
3. Treatment Options
Although numerous treatment options for male SUI exist,
including penile clamps, transurethral bulking agents, or
catheters (condom or indwelling), the most commonly
utilized surgical therapies performed include placement of a
male sling or AUS.
3.1. Male Sling. Since its initial introduction, the male
sling has become increasingly utilized in cases of low-to-
moderate volume (1–3 pads/day) incontinence. Although
severalvariationsofthemaleslingarecurrentlyavailable,the
threesubtypeswiththemostreportedseriesavailableinclude
the BAS, RTS, and ARS.
Bone-anchoredslingsresultincompressiontothebulbar
urethra through placement of a synthetic or organic mesh
which is secured to the inferior pubic ramus using six
titanium screws. Sutures are subsequently secured to the
screws and mesh material and tightened to result in ap-
propriate tensioning. Following initial reports of degrada-
tion of organic materials, synthetic mesh (InVance; AMS,
Minnetonka, Minnesota) has become the most commonly
utilizedmaterialwiththeBAS[18].SeeFigure 1forgraphical
representation of BAS placement.
A second category of available male slings includes the
RTS, with the AdVance (AMS, Minnetonka, Minnesota) and
I-Stop TOMS (CL Medical, Lyon, France) slings most com-
monly employed. In contrast to the BAS which utilizes
anchored sutures, the RTS is self-anchored with bilateral
polypropylenemesharmsplacedinatransobturatorfashion.
The sling portion is secured at the proximal bulbar urethra
with continence achieved through subsequent elevation of
the urethra.
Several reports have examined preoperative character-
istics, surgical techniques, and postoperative management
principles which have been associated with improved out-
comes with RTS placement [29–31]. Preoperative character-
istics found to be predictive of worsened outcomes include
weakened residual sphincter function, incomplete sphincter
closure, and lack of elongation of the coaptive sphincterAdvances in Urology 3
Figure 1: Graphical representation of the bone-anchored sling.
Figure 2: Graphical representation of the retrourethral transobtu-
rator sling.
zone. Intraoperative and postoperative factors associated
with improved outcomes include tunneling of the sling arms
into subcutaneous tissues to improve ﬁxation, placing ﬁve or
more stitches, using nonabsorbable stitches, and minimizing
postoperative activity to reduce dislodgement. See Figure 2
for graphical representation of RTS placement.
Similar to RTS, ARS (Reemex, Neomedic Interna-
tional, Terrasa, Spain; and Argus, Promedon SA, Cordoba,
Argentina) are surgically placed at the proximal bulbar ure-
thra, with traction sutures placed retropubically. The sutures
are then tensioned at the level of the rectus fascia utilizing
either a “veritensor” (Reemex) device or silicone columns
and washers (Argus) to provide an appropriate level of ure-
thral compression. See Figure 3 for graphical representation
of ARS placement.
A fourth category of sling which has recently been intro-
duced is the quadratic sling (Virtue, Coloplast, Humlebaek,
Denmark).Theslingconsistsofabroad-basedmeshmaterial
placed over the bulbar urethra similar to the BAS. It is
Figure 3: Graphical representation of the adjustable retropubic
sling.
then self-secured with four mesh arms which are placed in
both a transobturator (two arms) and prepubic (two arms)
manner. The limbs may then be further secured to create
additional points of ﬁxation as needed. See Figure 4 for
graphical representation of quadratic sling placement.
The hypothesized mechanism for improved continence
with the various sling designs varies and is not thoroughly
understood. Bone-anchored slings likely achieve direct com-
pression of the bulbar urethra with subsequent increases in
outﬂow resistance. In contrast, the mechanism for the RTS
is based on the hypothesis that mild/moderate SUI results
fromcompromiseofperiurethralsupportingstructures[32].
Through proximal placement of the mesh material, the
dynamics of the bulbar urethra are modiﬁed to result in
functional extension of the membranous and angulation of
the bulbar urethra. The mechanisms for improved SUI with
the ARS and quadratic sling are currently unknown and
may result from a combination of urethral compression and
angulation.
3.2. Artiﬁcial Urinary Sphincter. Since its popularization in
1978, the AUS has arguably remained the gold-standard
therapy for SUI. The currently available model, AMS 800
(AMS, Minnetonka, MN), consists of a pump, pressurized
reservoir, and sphincter cuﬀ.C u ﬀ sizes range from 3.5
to 14.0cm, and the reservoir is available in ﬁve pre-set
pressures (41–50, 51–60, 61–70, 71–80, and 81–90cm H2O)
to adapt to various patient requirements. When cycled, the
pump functions to actively shunt ﬂuid from the cuﬀ to
the reservoir via a unidirectional valve, which additionally
prevents uncontrolled retrograde transmission of ﬂuid to the
cuﬀ. A reﬁll-delay resistor maintains the cuﬀ in an open
state to permit voiding and subsequently permits transfer of
ﬂuid from the reservoir to the cuﬀ. The pump also contains
a deactivation button which permits the cuﬀ to be placed
in a locked “open” state when needed or to potentially4 Advances in Urology
Figure 4: Graphical representation of the quadratic sling.
reduce urethral atrophy [40]. See Figure 5 for graphical
representation of AUS single cuﬀ placement.
Placement of the AUS is performed via a similar dis-
section to that of male sling insertion. The proximal bulbar
urethra is identiﬁed, isolated, and measured, and an appro-
priately sized cuﬀ is placed circumferentially. The reservoir is
placed deep to the rectus sheath, and the pump is located
in the inferior hemiscrotum. Contrast may be instilled in
lieu of saline to permit future trouble shooting of the
device, and the device is connected and cycled. Variations
to placement of the AUS are frequently utilized in cases
of recurrent incontinence following prior AUS placement,
urethral atrophy, or prior device erosions/infections. In these
settings, an AUS may be placed in “tandem” with an existing
AUS and secured to the reservoir and pump with a Y-
connectdevice[41].SeeFigure 6forgraphicalrepresentation
of AUS tandem cuﬀ placement. Alternatively, a transcorporal
dissection of the proximal bulbar urethral may be performed
or alternative materials may be placed around the urethra
including porcine small intestinal submucosa at the time of
AUS cuﬀ placement to provide additional tissue bulk [42–
44].
In patients presenting with persistent incontinence fol-
lowing prior sling placement, an AUS may be placed, with
dissection performed similar to a primary AUS procedure.
In cases where the prior mesh is encountered, this may be
incised without need for complete excision, and the cuﬀ
placed in the standard fashion.
4. Results
Multiple series are currently available reporting outcomes
of the various male sling techniques and AUS implantation.
However, given the nature of the studies performed and
methodology for reporting, outcomes should be interpreted
with caution. There is currently no accepted standard meth-
od for reporting pre- and postoperative degrees of incon-
tinence or any consistent method for deﬁning success with
treatment. The majority of studies have poorly or undeﬁned
inclusion/exclusion criteria with signiﬁcant heterogeneity of
the patient population including inconsistent inclusion of
Figure 5: Graphical representation of the single-cuﬀ artiﬁcial
urinary sphincter.
Figure 6: Graphical representation of the tandem-cuﬀ artiﬁcial
urinary sphincter.
patients with varied etiologies for SUI or prior radiation
therapy.Thesefactors,amongothers,limittheabilitytodraw
comparisons between studies and techniques.
4.1. Male Sling. As the BAS has been available and utilized
for a longer period of time than other slings, more studies
are currently available for review with longer mean/median
follow up periods. For the purposes of the current review,
studies were included if they were published within the past
10 years and examined synthetic sling placement only, as
organic sling material is no longer commonly employed.
Overall results of the BAS demonstrated cure rates rang-
ingfrom37to67%withimprovementnotedinanadditional
10–40%[19–28].Thewiderangeofresultsislikelysecondary
to surgical method, deﬁnitions for continence utilized andAdvances in Urology 5
also may be due to a migration of case complexity. More
recent reports have included an increased number of pa-
tients with prior radiation therapy and those with more
severe preoperative incontinence. Several studies have noted
signiﬁcance in the association of preoperative continence
and postoperative success rates with conﬂicting reports on
the impact of radiation on overall success. Complications
commonly reported include infection (2–15%), erosion (0–
3%), de novo urgency/overactivity (0–14%), pain (0–73%)
which typically resolves within 4 months, and sling removal
(0–13%). See Table 1 for comparison of outcomes among
patients undergoing BAS placement.
ResultsfromplacementoftheRTShavesimilarlydemon-
strated resolution or improvement in males with mild-to-
moderateSUIin9–62%and16–46%ofpatients,respectively
[33–39, 58]. With the notable exception of Cornel and
colleagues who reported a success rate of 9% and failure
rate of 46% among 35 patients, other studies report higher
cure rates of 52–74% with improvements noted in and
additional 16–27%. Complications reported with the RTS
include temporary urinary retention <2 weeks (0–24%),
urethralinjury(0–3%),pain(0–34%),needforslingremoval
(0–4%), and dysuria (0–14%).
It is notable that four studies examining RTS were
prospectively designed, with three accruing over 110 patients
[33, 34, 38, 58]. As with the BAS groups, improved outcomes
were noted among patients with decreased preoperative in-
continence, with a trend towards increased failures noted
among patients with preoperative radiation therapy [38].
Two studies of interest investigated the role for RTS
as a salvage technique in cases of recurrent incontinence
following prior anti-incontinence surgery. Christine and
colleagues reviewed 19 patients undergoing RTS in patients
with recurrent incontinence following prior AUS placement
[35]. Patients had self-reported pre-op pad usages of 2–
5ppd. Following RTS placement, 15/19 (79%) reported
requiring 0ppd, with the remaining 4/19 (21%) describing
improvement. Approximately half of the patients did not
require reactivation of the sphincter.
Similarly, Soljanik and colleaguesreported on 29patients
undergoingRTSfollowingapreviouslyfailedslingprocedure
with preoperative mean pad requirement of 4.3ppd. At 17
months followup, results demonstrated resolution of incon-
tinence in 10/29 (35%) with improvement noted in an addi-
tional 16/29 (55%). These studies highlight the potential role
for male sling placement as a potential adjunctive/salvage
treatment; however, further validation is required prior to
its consideration as a routine salvage measure. See Table 2
forcomparisonofoutcomesamongpatientsundergoingRTS
placement.
A third category of currently available slings includes the
ARS, with the Argus (Promedon SA, Cordoba, Argentina)
and Reemex (Neomedic International, Terrasa, Spain) slings
most commonly utilized. Results of initial and longer-
term followup demonstrate success rates of 13–100% with
larger series reporting rates of 54–79% [45, 47–52]. Patients
required adjustments in 10–100% of cases, many of which
required repeated anesthesia. Complication rates were noted
to be signiﬁcantly higher compared to other sling categories
with infections (5–7%), erosion (3–13%), explantation (2–
35%), bladder perforation (5–29%), retention (35%), and
perinealpain(4–38%) mostcommonlyreported. See Table 3
for comparison of outcomes among patients undergoing
ARS placement.
One study of interest conducted by Tuygun and col-
leagues retrospectively compared the Argus (Promedon
SA, Cordoba, Argentina) sling to the AMS 800 (AMS,
Minnetonka, Minnesota) AUS [46]. A total of 16 patients
withpriorAUSerosionsweretreatedwitheitherARS(n = 8)
or repeat AUS (n = 8). Results demonstrated cure rates of
5/8 (63%) versus 1/8 (13) and improvement rates of 2/8 (25)
versus 1/8 (13) for the AUS and sling, respectively.
A more recently released sling is the Virtue quadratic
sling (Coloplast, Humlebaek, Denmark) with minimal data
available on initial outcomes. The only currently published
study was performed by Comiter and colleagues who re-
ported initial outcomes of 22 patients undergoing sling
placement with pre- and postoperative retrograde leak point
pressurestested[59].Resultsdemonstratedimprovementsin
the leak point pressure from preoperative 33 ± 9t o6 9±
6cmH 2O. Although these results are an encouraging proof
of concept, further data is currently pending.
4.2. Artiﬁcial Urinary Sphincter. Multiple series have re-
ported on long-term AUS outcomes [53–57]. As the AUS has
been available for use for a longer period of time than the
male slings, mean follow-up periods are greater and range
from 3 to 7.7 years. Similar to the reports on male slings,
the deﬁnition for postoperative continence varies by study,
with the most commonly utilized deﬁnition of 0-1 pads as
being “continent.” Results demonstrate overall continence
rates of 59–91% with the two studies which included over
100 patients reporting 69% and 82% success [54, 56]. Kim
and colleagues reported on the long-term durability of the
AUS and noted that patients with <4 years of follow-up
experienced continence rates of 76% which increased to 89%
in those with >8 years followup. This result appeared to
correlate with the ﬁnding that the far majority of surgical
revisions required were performed in the ﬁrst 36–48 months
with an overall, long-term mechanical failure rate of 36%
noted at 10 years [54].
Similarly, Lai and colleagues reported on 270 patients
with a mean followup of 3 years including some patients
with >12 years followup [56]. Mean preoperative and
postoperative pad use was 5.3 and 1.1ppd, respectively.
Thirty-four percent (60/176) of patients who presented with
postprostatectomy incontinence (PPI) had undergone prior
radiation therapy, with 34% and 43% of all PPI patients
demonstrating detrusor instability and decreased bladder
compliance on urodynamic studies, respectively. Patients
who had previously undergone peri-urethral bulking agent
administration or male sling placements did not demon-
strate a decreased success rate compared to those who
had not undergone similar procedures. Twenty-two percent
(59/270) of patients ultimately required repeated surgical
intervention secondary to complications at a median time of
14.4 months.6 Advances in Urology
Table 1: Comparison of results of bone anchored sling placement in adult males with SUI.
Study Pts
(No.)
Mean/med
f/u (mo)
Pre-op
continence
(mean/med)
Success def Success
(%)
Improved
(%)
No
improvement
(%)
Complications
(%) Notes
Cespedes and
Jacoby [19] 58 6 26 (45) 11 (19) 21 (36) None
Ullrich and
Comiter [20] 36 25 ≥3ppd 0ppd 24 (67) 9 (25) 3 (8) None
Mean pads
decreased from
4.6 to 0.64
Comiter [21]4 8 4 8 ≥3ppd 0ppd 31 (65) 10 (21) 7 (15)
Infection 1 (2),
erosion 1 (2),
perineal pain ×
3 months 7 (16),
2( 4 )s c r e w
dislodgement
Mean pads
decreased from
4.6 to 1.0
Castle et al. [22]3 8 1 8 ≤1ppd 15 (40)
Infection 3 (8),
erosion 1 (3),
majority with
signiﬁcant
perineal pain ×
3-4mo
Gallagher et al.
[23] 31 15 ≤1ppd 18 (58)
Infection 2 (6),
Sling removal 4
(13)
3pts lost to f/u,
4pts w/sling
removal
Fischer et al.
[24] 62 15 Pad wt
352g ± 43
PGI-I 1
question 36 (58) 6 (10) 26 (42)
Infection 3 (5),
erosion 1 (2),
pain >5m o n t h s
5 (8), total 13
(21)
Prospective
study; 71%
chance of
success if preop
pad weight
<423g
Guimar˜ aes et al.
[25] 62 28 0ppd 40 (65) 14 (23) 8 (13)
Infection 2 (3),
pain 12 (19),
bone anchor
dislodgement 1
(2)
3 year f/u
w/21/30 (70), 4
year 8/12 (67)
successful
Giberti et al.
[26] 40 35 pad weight
0-1g 22 (55) 5 (13) 13 (33)
Infection 6 (15),
de novo
detrusor
overactivity 2
(5), pain 29 (73)
Athanasopoulos
et al. [27] 43 24 See notes ≤1ppd 22 (51) 8 (19) 13 (30)
Infection 5 (12),
ne novo urgency
6 (14), pain 1
(2)
Pre-op
incontinence:
1-2 pads in 6/43
(14), 3–5 pads
in 23/43 (53),
and ≥6p a d si n
14/43 (33)
Carmel et al.
[28] 45 36 0ppd 16 (36) 18 (40) 11 (24)
Infection 1 (2),
pain ≤ 3
months 10 (22)
12pts (27%)
w/preop
radiation
Common complications following AUS placement in-
clude urethral atrophy resulting in recurrent incontinence
(4–10%), erosion (4–10%), infection (1–14%), and mechan-
ical failure (0–29%). See Table 4 for comparison of outcomes
among patients undergoing AUS placement.
Numerous additional studies have reported on salvage
therapies available for prior AUS failures including tandem
cuﬀ placement, cuﬀ downsizing, transcorporal cuﬀ, and the
use of biologic materials as a urethral bulking agent [41–
43, 60–62]. Although a formal review of salvage therapiesAdvances in Urology 7
Table 2: Comparison of results of retrourethral transobturator sling placement in adult males with SUI.
Study Pts
(No.)
Mean/med
f/u (mo)
Pre-op
continence
(mean/med)
Success def Success
(%)
Improved
(%)
No
improvement
(%)
Complications
(%) Notes
Rehder et al.
[33] 118 12 2.3ppd ≤1ppd 87 (74) 20 (17) 11 (9)
Retention 6 (5),
perineal pain 23
(20)
Prospective
Cornel et al.
[34] 35 12
0ppd, <2g
urine
loss/day
3 (9) 16 (46) 16 (46)
Removal 1 (3),
retention 1 (3),
mod-severe pain
<3m o n t h s1 2
(34)
Prospective,
2-center study
∗Christine and
Knoll [35] 19 13 0ppd 15 (79) 4 (21) 0 (0) None
Pts w/recurrent
incontinence
after AUS
placement
∗Soljanik et al.
[36] 29 17 4.3ppd 0ppd 10 (35) 16 (55) 3 (10)
Urethral injury
1( 3 ) ,r e t e n t i o n
<2wks 9 (24)
Pts previously
failed sling
placement
∗Bauer et al.
[37] 24 18 4.5ppd ≤1ppd 6 (25) 6 (25) 12 (50) Removal 1 (4)
All patients with
RP and adjuvant
radiotherapy
Cornu et al. [38] 136 21 2.1ppd 0ppd 84 (62) 22 (16) 30 (22) Pain 14 (10),
dysuria 19 (14)
Prospective
study; failure
ass’d w/24-hr
pad >200g,
trend toward
radiation
therapy
Bauer et al. [37] 126 27 4.9ppd ≤1ppd 65 (52) 30 (24) 31 (25)
Removal 2 (2),
retention
<10wks 19 (15),
persistent pain 1
(1)
Prospective
study; 17pts
(14%) with
pre-op radiation
Berger et al. [39] 26 22 5.6ppd 0ppd 16 (62) 7 (27) 3 (12) Pain ≤4w e e k s5
(19)
∗Salvage patient populations.
and outcomes is beyond the scope of the current review,
one recent study with long-term followup examined primary
single versus double cuﬀ AUS placement and found no sta-
tistical diﬀerence in continence outcomes between treatment
groups [55]. This would argue against the routine placement
of tandem cuﬀs as a primary treatment modality. Similarly,
the above procedures are predominantly reserved for use as a
salvage technique rather than primary therapy.
Many studies have reported signiﬁcant improvements in
qualityoflifemeasureswithboththemaleslingandAUS[28,
37, 39, 49, 63]. This likely highlights the signiﬁcant impact
that SUI has on overall quality of life as well as the improve-
ments noted with its treatment. It is also important to
note that with either male sling or AUS placement, it is
uncommon to experience a complete resolution of inconti-
nence with a return to preexisting baseline continence levels.
As such, it is important to appropriately counsel patients
as to reasonable postoperative expectations and potential
complications.
5. Complications
Complications resulting from either male sling or AUS
implantationmaybecategorizedasoccurringintraoperative,
early postop (<90 days) or late postop (>90 days). Intraoper-
ative complications may include urethral injury occurring at
the time of urethral dissection or passage of a trocar for male
sling placement. If a small injury is recognized, placement of
the AUS/male sling may continue at a separate site to prevent
subsequent erosions. A large urethral injury should be
repaired primarily with the procedure aborted and a catheter
placed. Bladder injuries occurring during trocar passage may
be managed with repassing of the trocar and subsequent8 Advances in Urology
Table 3: Comparison of results of adjustable retropubic sling placement in adult males with SUI.
Study Pts
(No.)
Mean/med
f/u (mo)
Pre-op
continence
(mean/med)
Success def Success
(%)
Improved
(%)
No
improvement
(%)
Complications
(%) Notes
Romano et al.
[45] 48 45 0ppd 31 (66) 6 (13) 10 (21)
Infection 3 (6),
erosion 6 (13),
removal 9 (19),
pain 2 (4)
Argus sling;
adjustment
required in 5
(10)
∗Tuygun et al.
[46] 8 10 6.8ppd 0ppd 1 (13) 1 (13) 6 (75) Pain 3 (38)
Argus sling; pts
w/prior AUS
erosion; study
compares AUS
to sling as
salvage option
Bochove-
Overgaauw and
Schrier [47]
95 27 See notes ≤1ppd 51 (54) 17 (18) 27 (28)
Infection 6 (6),
erosion 3 (3),
removal 11 (12),
total 55 (58)
Argus sling;
Pre-op
continence:
1-2ppd in
13/100, 3–5ppd
in 46/100, and
6–10ppd in
41/100
Dalpiaz et al.
[48] 29 35 5ppd 5 (17)
Infection 2 (7),
erosion 3 (10),
bladder
perforation 3
(10), retention
10 (35), removal
10 (35),
signiﬁcant pain
8 (27)
Argus sling;
Dissatisﬁed with
clinical outcome
21 (72)
H¨ ubner et al.
[49] 101 25
≤1g
20-min
pad test
80 (79)
Bladder
perforation 5
(5), infection 5
(5), erosion 13
(13), removal 16
(16), pain
<3wks 15 (15)
Argus sling;
adjustment
required in 39
(39)
Sousa-Escand´ on
et al. [50] 51 32 ≤1ppd 33 (65) 10 (20) 8 (16)
Infection 3 (6),
removal 1 (2),
bladder
perforation 5
(10), majority
with perineal
pain
Remeex sling;
multicenter
study;
adjustment
required in 51
(100)
Verdejo et al.
[51] 51 5 5 – 8 p p d ≤1ppd 5 (100) Remeex sling
Parra et al. [52] 15 19 5/12 (42) 4/12 (33) 3/12 (25)
Removal 3 (21),
readjustment 12
(86), bladder
perforation 4
(29), retention 5
(36)
Remeex sling
PPD: pads per day; PGI-I: Patient Global Impression of Improvement; RP: radical prostatectomy; RLPP: retrograde leak point pressure.
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Table 4: Comparison of results of single-cuﬀ AUS placement in adult males with SUI.
Study Pts (No.) Continence def
(pads/day)
Mean follow-up
(yr)
Success
(%)
Explantation
(%) Complications (%)
58 ≤2 4.2 91.4 20.3
Mechanical
failure 6.5
Arai et al. [53]
Infection 14
Erosion 4.7
124 0-1 6.8 82 36 (incl
revision)
Mechanical
failure 29
Kim et al. [54]
Infection 7
Erosion 10
25 0-1 6.2 61 16
Mechanical
failure 0
O’Connor et al.
[55] Infection 8
Erosion 8
Atrophy 4
218 0-1 3 69 27.1 (incl
revision)
Mechanical
failure 6
Lai et al. [56] Infection 5.5
Erosion 6
Atrophy 9.6
71 0-1 7.7 59 29 (incl
revision)
Mechanical
failure 25
Gousse et al.
[57] Infection 1.4
Erosion 4
catheterization for a period of several days postoperatively.
Giventherelativeincidenceofbladderinjurywithretropubic
sling placements, patients undergoing these procedures
shouldundergointraoperativecystoscopytoruleoutbladder
perforation.
Early postoperative complications include urinary reten-
tion, infection and/or erosion, perineal pain, and de novo
detrusor overactivity. Urinary retention typically occurs sec-
ondary to postoperative edema and resolves spontaneously
in the majority of cases. Persistent retention lasting >8
weeksmayindicateinappropriatesizingofthesphinctercuﬀ,
overtensioning of the sling, or sling malposition. Retention
is typically managed with in-and-out catheterization with
suprapubic tube placement required in rare cases. In the
case of AUS placement, it is the authors’ preference to
avoid indwelling catheters and to use a small (12F) straight
catheter when required in the postoperative period to reduce
the risk of development of catheter-related erosions.
Infections of the AUS device or sling material may be
secondary to unrecognized urethral erosion versus intraop-
erativecontamination.Preoperativepatientfactorsincluding
repeated device placements, prior erosions, and radiation
therapy all predispose patients towards a higher rate of post-
operativeinfections.Themostcommonlyisolatedorganisms
with infection include S. aureus, S. epidermidis, Enterococ-
cus, Methicillin resistant S. aureus, and gram-negative bacilli
[64]. Infections occurring beyond 90 days may be related to
hematogenous spread of bacteria at the time of additional
procedures.
Urethral erosions occurring early in the postoperative
period are likely secondary to unrecognized urethral injury
occurring at the time of surgical implantation. Device ero-
sions require explantation, even in the absence of infection,
with possible repeat AUS/sling placement performed several
months later pending suﬃcient recovery and absence of
urethral stricture development.
Postoperative perineal pain is more common with male
sling placement than AUS, with some authors noting pain
in 100% of male sling patients for periods up to 4 months.
Patients may additionally develop de novo detrusor overac-
tivity, which may be managed with anticholinergic therapy
as indicated.
Mechanical failure is unique to AUS devices and has been
showninonelong-termfollowupof100patientsundergoing
AUS to have 5- and 10-year device failure-free rates of 74.8%
and 70.1%, respectively [53]. Additional studies with follow-
up periods >5 years conﬁrm similar ﬁndings of device failure
rates of 25–34% [54, 57, 65].
6.PatientStratiﬁcation
The decision as to which procedure to perform in males
presenting with stress urinary incontinence is based on
several factors. Most commonly, male slings are oﬀered in10 Advances in Urology
cases of lower-volume incontinence (1–3 pads/day), or in
the setting of complicating patient factors including inability
to function the AUS pump. Placement of an AUS may be
performed with any degree of SUI and may be employed in
the setting of prior male sling failures.
There is currently no universally accepted standard by
which patients are stratiﬁed into receiving a male sling
versus AUS. Similarly, there are no currently accepted
objective measures by which men are formally evaluated
for stress incontinence. Evaluating clinicians may elect to
stratify patients based on subjective reporting of pad usage,
objectively obtained 24-hour pad weights, or by the degree
of SUI visualized on examination. This lack of consensus
on the clinical evaluation of males with SUI is mirrored in
the available published literature which similarly lacks an
accepted method of standard reporting.
Additionally, there are currently no publications which
directly compare results for the various treatments of male
SUI, and as such, it is not possible to directly compare
reported outcomes between studies. Based on the reported
literature available, it is not possible to deﬁnitively identify
one sling procedure as superior over another.
In general, available data on the various male slings have
shown a reduction in overall eﬃcacy in patients with pre-
surgical, higher volume incontinence (discussed further in
Section 4), and therefore AUS is typically chosen in these
cases. Alternatively, male slings may be preferred in cases
of diminished hand and/or cognitive ability, regardless of
degree of incontinence as this may avoid potentially serious
complications of urinary retention and its sequelae. Given
the lack of data and guidelines, the decision as to whether
to perform a male sling versus AUS depends on several
factors including patient preference, surgeon comfort, and
experience with the available procedures, and knowledge of
the currently available outcomes and complications of each
procedure.
Regardless of the treatment selected, it is important to
review with patients appropriate immediate and long-term
expectations following the procedure as well as potential
complications and need for additional procedures.
7.FuturePerspectives
The treatment of male SUI has evolved signiﬁcantly over the
past 40 years, with numerous improvements made to the
AUS and multiple variations of the male sling developed in
a relatively short period of time. And given the prevalence of
prostate cancer with need for ongoing treatments, there will
likely remain a signiﬁcant need for treatment of iatrogenic
SUI for the foreseeable future. It is anticipated that there
will be ongoing improvements to the AUS to increase
device longevity, reduce infectivity, and to better cater to
patientswithlimitedmanual/mentalcapability.Itissimilarly
expected that new variations and improvements to the
existing male slings will continue to be developed, with
further studies performed providing additional and longer-
term followup on previously installed slings.
Novel techniques and materials will emerge to meet
the ongoing need for alternative, minimally invasive, and
adjustable options for management of low-to-moderate
volume incontinence. This is particularly relevant in the
setting of the recent FDA announcement in July of 2011
regarding utilization of mesh in pelvic organ prolapse.
This may directly or indirectly impact the utilization of
mesh material in other applications, including male sling
placement.
More recently, investigators have examined the potential
use of stem cell therapy to directly treat the underlying
disease process. Several investigators have reported on the
successful creation of muscle- or adipose-derived stem
cells and hypothesized their potential use as a regenerative
treatment for iatrogenic injury to the native rhabdosphincter
[66–69]. Yamamoto and colleagues reported the use of
adipose-derived stem cell injection into the periurethral
tissues of two men with SUI following RRP performed at
least two years prior [70]. With limited followup at 12
weeks, both men experienced signiﬁcant improvements in
measured pad weights over a 4-day period. Although this
study has signiﬁcant limitations including the lack of a
control group treated with periurethral bulking injection
with adipose tissue alone, ﬁndings such as these will likely
lead to additional research on the potential for stem cell
therapy.
Similar to stem cell therapy, additional investigations
continue in identifying alternative bulking agents for use
as a periurethral injectable material [71]. Watanabe and
colleagues recently reported improved objective ﬁndings in
rats treated with adipose-derived mesenchymal stromal cells
compared to those treated with standard collagen injections
[72]. Although these treatments remain in the early stages
of research, they oﬀer potential signiﬁcant advantages over
currently available surgical therapies given their minimally
invasive approach without need for synthetic material/device
implantations.
8. Conclusions
Iatrogenic male stress urinary incontinence remains a sig-
niﬁcant problem impacting a large number of patients with
resultant impairment of quality of life. Patients presenting
with SUI should undergo a thorough history and physical
examination with additional studies obtained as indicated.
Several therapies are currently available for the treatment
of low-to-moderate volume incontinence including the AUS
and several variations of male slings (BAS, RTS, ARS, and
quadraticsling).Patientswithlarge-volumeincontinenceare
best managed with AUS when found to be an appropriate
surgical candidate. Complications of sling/AUS placement
include temporary retention, perineal pain, infections, ero-
sions, de novo urinary symptoms, and device malfunction.
Patients desiring surgical management of SUI should be
c o u n s e l e da st oe x p e c t e do u t c o m e sa sw e l la sp o t e n t i a l
complications.Advances in Urology 11
Abbreviations
ARS: Adjustable retropubic sling
AUS: Artiﬁcial urinary sphincter
BAS: Bone-anchored sling
PPD: Pad(s) per day
PPI: Postprostatectomy incontinence
SUI: Stress urinary incontinence
RP: Radical prostatectomy
RTS: Retrourethral transobturator sling
TURP: Transurethral resection of the prostate.
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